[Current and future therapeutic options for COVID-19].

Abstract

The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.

• Authors: Marloes Dankers, H Marjorie J M G Nelissen-Vrancken, Marjolein Y Berger, Marc J M Bonten, Joop M A van Gerven, Peter W A Kunst, Majon Muller, Marcel G M Olde Rikkert, Frits R Rosendaal
• Journal: Nederlands tijdschrift voor geneeskunde (Ned Tijdschr Geneeskd) Vol. 166 (07 21 2022) ISSN: 1876-8784 [Electronic] Netherlands
• Vernacular Title: Recente en toekomstige behandelingen bij covid-19.
• PMID: 36036702 (Publication Type: Journal Article)

Chemical References

• AT-511
• Adrenal Cortex Hormones
• Anti-Inflammatory Agents
• Antiviral Agents
• Phosphoramides
• Recombinant Fusion Proteins
• Guanosine Monophosphate
• ensovibep

Topics

• Adrenal Cortex Hormones
• Anti-Inflammatory Agents (therapeutic use)
• Antiviral Agents (therapeutic use)
• Guanosine Monophosphate (analogs & derivatives)
• Humans
• Phosphoramides
• Recombinant Fusion Proteins
• SARS-CoV-2
• COVID-19 Drug Treatment